HC Wainwright Reiterates Buy Rating for Indaptus Therapeutics (NASDAQ:INDP)

Indaptus Therapeutics (NASDAQ:INDP)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 339.56% from the stock’s previous close. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($1.44) EPS.

Indaptus Therapeutics Price Performance

INDP opened at $2.73 on Monday. The company has a market capitalization of $23.31 million, a price-to-earnings ratio of -1.48 and a beta of 1.28. Indaptus Therapeutics has a 1-year low of $1.56 and a 1-year high of $4.08. The business has a 50 day moving average price of $2.11 and a two-hundred day moving average price of $2.10.

Indaptus Therapeutics (NASDAQ:INDP) last released its earnings results on Wednesday, March 13th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Equities analysts expect that Indaptus Therapeutics will post -1.73 EPS for the current fiscal year.

Institutional Investors Weigh In On Indaptus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Indaptus Therapeutics by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock valued at $451,000 after acquiring an additional 5,517 shares during the last quarter. Northern Trust Corp acquired a new stake in shares of Indaptus Therapeutics during the 1st quarter valued at $41,000. Citadel Advisors LLC acquired a new stake in shares of Indaptus Therapeutics during the 4th quarter valued at $29,000. State Street Corp acquired a new stake in shares of Indaptus Therapeutics during the 1st quarter valued at $78,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Indaptus Therapeutics in the second quarter worth $51,000. Institutional investors and hedge funds own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial.